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ABSTRACT
Background: Congenital portosystemic shunt (cPSS) is one of the most common congenital 
disorders diagnosed in dogs. Hepatic encephalopathy (HE) is a frequent complication in dogs 
with a cPSS and is a major cause of morbidity and mortality. Despite HE been a major cause 
of morbidity in dogs with a cPSS, little is known about the cellular changes that occur in the 
central nervous system of dogs with a cPSS.
Objectives: The objective of this study was to characterise the histological changes in the cerebral 
cortex and cerebellum of dogs with cPSS with particular emphasis on astrocyte morphology.
Methods: Eight dogs with a confirmed cPSS were included in the study.
Results: Six dogs had substantial numbers of Alzheimer type II astrocytes and all cases had 
increased immunoreactivity for glial fibrillary acidic protein in the cerebral cortex, even if 
there were minimal other morphological changes.
Conclusions: This study demonstrates that dogs with a cPSS have marked cellular changes 
in the cerebral cortex and cerebellum. The cellular changes that occur in the cerebral cortex 
and cerebellum of dogs with spontaneously arising HE are similar to changes which occur in 
humans with HE, further validating dogs with a cPSS as a good model for human HE.
Keywords: Astrocytes; hepatic encephalopathy; dogs; portosystemic
INTRODUCTION
Congenital portosystemic shunt (cPSS) is one of the most common congenital abnormalities 
diagnosed in dogs [1]. Dogs with a cPSS usually have a single, extra-hepatic vessel that links 
the portal vein and the caudal vena cava, although a range of intrahepatic and extrahepatic 
vascular abnormalities have been described [2,3]. Dogs with a cPSS can present with a wide 
range of clinical signs such as poor growth and stunted development, gastrointestinal or 
urinary tract abnormalities or a range of neurological disturbances that are termed ‘hepatic 
encephalopathy’ (HE) [3-5]. Dogs can be screened with good sensitivity and specificity for 
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cPSS by measurement of serum bile acids and ammonia [6] and the abnormal vessel can be 
definitively identified in almost all cases by either abdominal ultrasonography, computed 
tomography or magnetic resonance imaging [7-9].
HE is one of the most significant complications observed in dogs with a cPSS. The clinical 
signs range from mild lethargy to ataxia, disorientation through to stupor and coma. Medical 
management with therapies such as lactulose and antibiotics or surgical attenuation of the 
aberrant vessel can improve HE in most dogs with a cPSS [10-12]. However, persistence or 
recurrence of HE following either medical or surgical treatment is one of the most common 
reasons why dogs with a cPSS are euthanased [3,10-12]. Furthermore, in a small proportion 
of dogs with a cPSS treated by surgery, the neurological signs can dramatically worsen post 
attenuation [13-17].
As HE is such a significant cause of morbidity and mortality in dogs with a cPSS, there is clear 
interest in understanding more about the underlying pathophysiology of HE. Ammonia has 
long been implicated in the development of HE and it has been shown that dogs with cPSS 
and HE have significantly higher ammonia concentrations than dogs with cPSS and no HE 
[18]. Further evidence that increased concentrations of ammonia is an important aspect of 
the pathophysiology of HE is the concept that ammonia crossing the blood-brain barrier 
is absorbed and metabolised by astrocytes as they synthesise glutamine from glutamate. 
The increased levels of cerebral glutamine leads to an increased osmotic pressure in the 
astrocytes that then become swollen. Histologically, this can be detected as single, paired, 
or larger groups of astrocytes with pale nuclei, termed ‘Alzheimer type II astrocytes’ [19,20]. 
However, the raised blood ammonia levels do not always correlate with the severity of clinical 
signs and other putative toxic factors such as glutamine [21], excitatory amino acids and/or 
mercaptans have been proposed as key molecules responsible for the neuronal dysfunction 
that leads to clinical signs of HE [22].
Recent studies have demonstrated that dogs with a cPSS and HE have a greater systemic 
inflammatory response than dogs with a cPSS and no HE [18,23,24]. In addition, systemic 
inflammation declines following successful treatment of HE [25]. Whole blood manganese, 
which is a potent neurotoxin, concentrations have also been found to be higher in dogs with 
cPSS than healthy controls. However, whole blood manganese concentrations do not differ 
between dogs with HE and dogs without HE and concentrations do not decline even when 
HE has been successfully treated [26,27]. Consequently, increased blood manganese is not 
considered to be a key driver of HE in dogs with cPSS.
Despite recent advances in understanding the pathophysiology of canine HE, little is known 
about the cellular changes that occur in the brains of dogs with HE. A small number of 
imaging studies have reported structural brain abnormalities in dogs with a cPSS [28-30] but 
no case series has been published which solely focuses on describing the histological changes 
in the brain of dogs with confirmed cPSS. There are only a small number of cases reported 
in the peer reviewed literature where these histological changes are described [14,15,31-
34]. These reports typically provide short descriptions of brain pathology and describe 
contrasting findings with histological changes in the brain varying from extensive necrosis of 
neurons to generalised polioencephalomalacia [14,31]. Consequently, the aim of this study 
was to undertake a more detailed histological evaluation of the changes that occur in the 
cerebral cortex and cerebellum of a cohort of dogs with a cPSS.
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MATERIALS AND METHODS
The veterinary pathology post mortem databases at the University of Edinburgh, University of 
Bristol, University of Cambridge and Royal Veterinary College were reviewed for cases of dogs 
with a confirmed cPSS. The age, breed, gender and type of cPSS were recorded. The clinical 
records prior to death or euthanasia were reviewed.
The paraffin wax-embedded tissue blocks used for the original pathological investigations 
were recut and sections (6 μm) were mounted on glass slides and stained with haematoxylin 
and eosin (H&E). Semi-serial sections were also immunolabelled for expression of glial 
fibrillary acidic protein (GFAP) (rabbit anti-cow GFAP, Z0334, Dako) and rabbit anti-cow 
S-100 (1:2,000, Dako Z0311) as described for HE in cases of PSS in man [35] using an indirect 
peroxidase method, following antigen retrieval (97°C, 20 min, citrate buffer) on a Dako 
Autostainer. Control brain tissue was obtained from three dogs that had been euthanized 
for a non-neurological disorder. The brain sections were independently evaluated by two 
pathologists without reference to the original pathological descriptions or diagnosis.
The presence of type II astrocytes in the cerebral cortex was assessed using a semi-
quantitative scale where:
- no type II astrocytes observed
+ occasional type II astrocytes present but in < 25% of ×20 objective fields
++ frequent type II astrocytes present; seen in 25%–50% of ×20 objective fields
+++ many type II astrocytes present; seen in 50%–75% of ×20 objective fields
++++ abundant type II astrocytes present in > 75% of ×20 objective fields examined
Astrocytes were considered to be of the Alzheimer type II type when enlarged, pale glial 
nuclei showing a vesicular nucleus with at least one basophilic nucleolus were visible. Often, 
they were present as paired nuclei (Fig. 1). Other pathological features present in the sections 
were also noted. The two pathologists then compared their results. Discordant results were 
discussed using a multi-headed microscope.
RESULTS
The age, gender and breed of the eight dogs included in the study are shown in Table 1. 
Three dogs had an intrahepatic cPSS and five dogs had an extrahepatic cPSS. Two dogs were 
euthanized due to poor response to medical management of HE. The remaining six dogs 
had surgical attenuation of the cPSS. One dog was euthanized four years after placement 
of ameroid constrictor due to persistent HE. One dog was euthanized 11 months following 
complete suture ligation of their cPSS due to persistent HE. The remaining four dogs died or 
were euthanized within 10 days of surgical attenuation of their cPSS due to persistent HE or 
immediate post-operative complications (Table 1).
All cases had evidence of Alzheimer type II astrocytes with six of the eight cases having 
substantial numbers of type II astrocytes (Table 2). Both pathologists scored the brain 
sections similarly. Where more than one section of cerebral cortex had been examined in the 
original investigations, all those sections were re-examined and a mean score for the level of 
type II astrocytes determined (Table 2).
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The type II astrocytes were found mainly in the cerebral cortex and tended to follow a 
laminar pattern, associated with mild laminar oedema in most cases (Fig. 1, Table 2). 
Neuronal ischaemic necrosis (i.e. small, angular, eosinophilic neurones) reported in other 
studies was not evident although occasional satellitosis was observed (Fig. 1). On review of 
the clinical history alongside the histological assessment of the brain samples, there was 
no clear correlation between the number of type II astrocytes detected and the duration 
or severity of clinical disease. For the cases where more than one wax block of brain tissue 
was available, there was little variation in the number of type II astrocytes between sections 
(and therefore areas) of cerebral cortex, except for case 6. All eight cases showed increased 
immunoreactivity for GFAP and S-100 (Fig. 1) within the cerebral cortex. While there is a 
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Fig. 1. Histological images from dogs included in the study. All histology images were from dogs which had HE 
apart from E which is included as non-neurological disease control to enable GFAP staining to be compared 
between brain tissue from a dog with a non-neurological disorder and a dog with HE. (A) Cerebral cortex showing 
laminar distribution of pathology (arrows) (H & E). (B) Cerebral cortex showing occasional neuronal satellitosis 
with presumed microglia (arrow) (H & E). (C) Cerebral cortex showing Alzheimer type 2 astrocytes (arrows) (H 
& E). (D) GFAP immunolabelling of affected area of cerebral cortex. (E) GFAP immunolabelling of similar area to 
D, taken from a normal adult dog. (F) S-100 immunolabelling of affected area of cerebral cortex showing paired 
astrocyte nuclei (arrow). 
HE, hepatic encephalopathy; GFAP, glial fibrillary acidic protein; H & E, hematoxylin and eosin.
general increase in GFAP immunoreactivity in HE, the Alzheimer Type II astrocytes do not 
show increased GFAP immunoreactivity whereas they do for S-100 (Fig. 1).
There was little evidence of white matter vacuolation, either within the core of cerebral white 
matter tracts or at the border between these tracts and deep grey matter in any of the 8 cases. 
Examination of the cerebellum from the 5 cases where material was available to this study 
revealed focal areas of Purkinje cell loss in 2 cases.
DISCUSSION
The main finding of this study was the high prevalence of Alzheimer type II astrocytes in 
a laminar pattern within the cerebral cortex of dogs with a cPSS and HE, together with an 
increase in GFAP immunoreactivity in the same areas of the brain. Although type II astroctyes 
are usually weakly GFAP positive [19,20,36] this study suggests that there is a more general 
activation of astrocytes in the affected areas of the brain, not all of which proceed to the type 
II astrocyte phenotype. To date, there have been limited descriptions of brain pathology 
in dogs with a cPSS. In two dogs which died following surgical attenuation of their cPSS, 
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Table 1. Clinical summary of cases
Signalment Types of cPSS Treatment
3-month-old FE Labrador Central divisional intrahepatic Poor response to medical management, euthanized 1 month post diagnosis.
7-month-old ME Crossbreed Portocaval extrahepatic Poor response to medical management, euthanized 4 days post-diagnosis.
6-year-old MN Miniature Schnauzer Extrahepatic Ameroid constrictor placed around cPSS. Euthanized 4 years post surgery following 
development of HE.
FN Dandie Dinmont Terrier Extrahepatic Cellophane band placed around cPSS, euthanized 4 days post surgery due to 
gastrointestinal haemorrhage.
8-year-old FN Cairn Terrier Portocaval extrahepatic Partial suture ligation performed. Develop seizures 2 days post-surgery. Euthanized 
4 days post-surgery due to persistent seizures, which were refractory to medical 
management.
4-month-old ME Flat Coated Retriever Left divisional intrahepatic Partial suture ligation performed. Died 2 days post-surgery due to gastrointestinal 
haemorrhage.
14-month-old ME Labrador Central divisional intrahepatic Partial suture ligation performed. Euthanized 10 days post-surgery due to 
gastrointestinal haemorrhage.
12-year-old ME Crossbreed Splenoazygous extrahepatic Complete ligation performed, euthanized 11 months post-surgery due to persistent HE.
cPSS, congenital portosystemic shunt; FE, female entire; ME, male entire; MN, male neutered; FN, female neutered.
Table 2. Histological summary of cases
Dog 
number
Number of slides examined Comment/description Type 2 
astrocytes
1 5 (cerebral cortex × 4; cerebellum × 1) Scant type II astrocytes. No cortical laminar vacuolation. Mild vacuolation of internal capsule and 
major rami.
+
2 1 (cerebral cortex with basal nuclei × 1) Abundant Type II astrocytes in cerebral cortex (laminar pattern) but not in basal nuclei; occasional 
neuronal satellitosis. No WM vacuolation.
+++
3 1 (cerebral cortex × 1) Laminar cortical vacuolation with type II astrocytes. ++
4 1 (cerebral cortex × 1) Mild hydrocephalus with reduced corpus callosum. Laminar cortical gliosis with moderate 
numbers of type II astrocytes.
++
5 5 (cerebral cortex × 4;cerebellum × 1) Mild hydrocephalus with thinning of cerebral cortex. Mild, laminar cortical vacuolation and 
perineuronal spaces. Variable number of type II astrocytes depending on area of cortex examined. 
Mild perivascular lymphocytic cuffing.
+ → ++
6 4  (thalamus and cerebral cortex × 2; 
cerebellum × 1; spinal cord × 1)
Mild to moderate numbers of type II astrocytes in the little cortical tissue present. Type II 
astrocytes present in spinal cord.
+ → ++
7 2 (cerebral cortex × 1; cerebellum × 1) Laminar cortical oedema/vacuolation. Mild numbers of type II astrocytes in cortical section only. +
8 4 (cerebral cortex × 3; cerebellum × 1) Cortical laminar oedema with vacuolation. Abundant type II astrocytes. +++ → ++++
The number of type 2 astrocytes were assessed using a semi-quantitative approach as outlined in the Materials and Methods. Severity scores in parentheses 
indicates that some brain areas showed this severity whereas most brain areas showed the other severity indicated (i.e. some variation between tissue sections 
was observed).
WM, white matter.
post-mortem examination revealed severe neuronal necrosis in one dog and multifocal, 
suppurative, necrotising bacterial encephalitis in the second case [15]. The presence of type II 
astrocytes was not reported. In another case report of two dogs which died following ligation 
of cPSS, the main post-mortem finding was ischemic change affecting neurons [32]. In two 
dogs which died following gauged attenuation of cPSS, extensive necrosis of neurons in 
the cerebral cortex with dilation of blood vessels, perivascular infiltration of leukocytes and 
histiocytes, and activation of endothelium in arterioles was reported [31]. In a review of three 
dogs that had died after surgical ligation of cPSS, generalised polioencephalomalacia with 
spongiform leukoencephalopathy was found in two dogs and multifocal, mild spongiform 
degeneration of the cerebral cortex in another [14]. One of the few reports to describe 
Alzheimer type II astrocytes was a single case report of a dog with a cPSS [34].
Our study is the first detailed report of the pathological changes of the cerebral cortex from 
a series of dogs that had a spontaneously arising portosystemic shunt and a history of HE, 
uncomplicated by secondary encephalitis. Ischaemic neuronal necrosis was not a feature 
in the current study and white matter vacuolation was either mild or absent. Many of the 
classical accounts of HE in ruminants or other herbivores indicate that vacuolation of cerebral 
white matter tracts, or vacuolation at the white matter-grey matter interface is a diagnostic 
feature [20,36]; this pattern of vacuolation was not observed in the present study, supporting 
previous suggestions that such vacuolation is less common in dogs than larger animals and 
that there may be species differences in nature of HE pathology [36].
We have clearly demonstrated that Alzheimer type II astrocytes are a common feature in 
dogs with HE. In addition, and not previously reported, an astrocyte activation, reflected in 
increased GFAP immunoreactivity, was detected; this could be considered as a non-specific 
response to disturbances of cerebral homeostasis. Alzheimer type II astrocytes are thought to 
represent proliferating astrocytes—supported by thymidine incorporation studies following, 
for example, administration of radiolabelled methionine sulphoxide (inhibits glutamine 
synthetase and promotes local ammonia production in the brain)—and are found most 
frequently in the cerebral cortex. In this study, Alzheimer type II astrocytes were observed 
in the cerebral cortex, cerebellum and in one case also the spinal cord, which was available 
for review. In most cases, these cells were associated with a laminar pattern of pathology 
in the cerebral cortex with oedema (microvacuolation) of grey matter. Although ischaemic 
neurones were sparse, this laminar pattern is reminiscent of laminar cortical degeneration 
that occurs in some other toxic and metabolic neuropathologies secondary to cortical glucose 
deprivation in certain animal species [20,36].
There was no clear evidence of a difference in cerebral cortex pathology in dogs that were 
euthanized due to intractable HE or dogs that died shortly after surgical attenuation of their 
cPSS. The development of post-operative gastrointestinal haemorrhage and/or seizures 
following surgical reduction of porto-systemic shunting is a well-established complication 
of cPSS attenuation [3,14,15,31,32,37]. For example, case 5, which was euthanized following 
development of post attenuation seizures, had similar pathological changes to case 2 which 
had HE and did not undergo surgery. The lack of observed differences may relate to the 
relatively small numbers in each subgroup or due to histological changes in other areas of the 
brain not reviewed in this study.
The histological changes in the brains of humans with HE have been widely reported and 
typically involve characteristic changes in astrocyte morphology [38-42]. Classical changes 
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which occur in astrocytes in human patients with HE include swelling of the nucleus, 
margination of chromatin and glycogen deposits which are collectively defined as ‘Alzheimer 
type II’ astrocytes [38-42]. Although rare compared to dogs, over three hundred cases of 
cPSS have been reported in humans [43]. Neuropathological findings in humans mirror 
our results, with Alzheimer type II astrocytes in the cerebral cortex being a key pathological 
finding in humans with a cPSS [38].
This study further demonstrates the merit of investigating dogs with spontaneously arising 
cPSS as a model for human HE. The type and distribution of lesions observed in this study 
is more consistent with that of portosystemic shunt pathology in man than it is of HE in 
other domestic species such as cattle and horses [19]. A recent review of experimental 
models of HE highlighted the need for better validated models of human HE [44]. In terms 
of HE resulting from portocaval shunting in the absence of parenchymal liver disease, the 
International Society for HE and Nitrogen Metabolism Commission (ISHEN) highlighted the 
need for models to have evidence of portal-systemic shunting, a range of encephalopathic 
signs, hyperammonaemia, a precipitating factor and clinical response to established 
treatments [44]. There is now a growing body of evidence that has demonstrated that these 
requirements are met in dogs with a spontaneous cPSS. For example, inflammation and 
hyperammonaemia have been shown to be key drivers of both human and canine HE [18,45]. 
Importantly, the ISHEN guidelines highlighted the need for these models to have evidence 
of Alzheimer type II astrocytes. This study indicates that this requirement has now been 
satisfied which further demonstrates that dogs with a cPSS are a good model for human HE. 
Furthermore, our study provides additional evidence that the biology of HE can be studied 
without the need to induce disease in otherwise healthy animals.
In summary, this study has described the histological changes observed in the cerebral cortex 
and cerebellum of dogs with a cPSS. Numerous Alzheimer type II astrocytes were observed 
in the majority of cases. Our study demonstrates that the histological changes that occur in 
dogs with a cPSS are very similar to the changes observed in humans with HE underlying 
the merit of a ‘One Health’ approach to investigation of this disorder which could lead to 
therapeutic advances for both species.
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